Brilaroxazine

Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA) /serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (Ki=1.5 nM) and 5-HT2A (Ki=2.5 nM), and has antagonist activity at 5-HT2B (Ki=0.19 nM), and 5-HT7 (Ki=2.7 nM) receptors[1]. Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo[2].

Product Specifications

CAS Number

[1239729-06-6]

Product Name Alternative

RP5063

UNSPSC

12352005

Target

5-HT Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/brilaroxazine.html

Concentration

10mM

Purity

98.82

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1NC2=CC(OCCCCN3CCN(C(C=CC=C4Cl)=C4Cl)CC3)=CC=C2OC1

Molecular Formula

C22H25Cl2N3O3

Molecular Weight

450.36

References & Citations

[1]Reviva Pharmaceuticals Reports RP5063 Positive Efficacy Results for Memory Deficits|[2]Bhat L, et al. Evaluation of the effects of RP5063, a novel, multimodal, serotonin receptor modulator, as single-agent therapy and co-administrated with sildenafil, bosentan, and treprostinil in a monocrotaline-induced pulmonary arterial hypertension rat model.Eur J Pharmacol. 2018 May 15;827:159-166.|[3]L. Bhat, et al. Rp5063 Prevents Monocrotaline Induced Pulmonary Arterial Hypertension In Rats.